POSTWEANING PLASMA CONCENTRATIONS OF LUTEINIZING HORMONE AND ESTROGENS IN SOWS: EFFECT OF TREATMENT WITH PREGNANT MARE’S SERUM GONADOTROPIN OR ESTRADIOL-17β PLUS PROGESTERONE

1979 ◽  
Vol 59 (1) ◽  
pp. 159-166 ◽  
Author(s):  
G. W. DYCK ◽  
W. M. PALMER ◽  
S. SIMARAKS
Keyword(s):  
Luteinizing Hormone ◽  
Plasma Concentrations ◽  
Treated Group ◽  
Linear Increase ◽  
Control Group ◽  
History Of ◽  
Serum Gonadotropin ◽  
Effect Of Treatment ◽  
Secretory Pattern ◽  
Estradiol 17Β

The plasma concentrations of luteinizing hormone (LH) and estrogens (E) were determined for 12 sows, from a herd with a history of postweaning anestrus, from the day of weaning to 32 days after weaning (trial I). A linear increase in plasma LH and E was observed in six sows which remained in anestrus (LH, 0.32–0.47 ng/ml; E, 16.1–24.7 pg/ml). These concentrations were similar to those observed in cycling sows during diestrus. In the remaining sows concurrent peaks of LH and E were observed during proestrus and estrus. In a second trial, two groups each of five sows were treated with a single injection of pregnant mare’s serum gonadotropin (PMSG, 1500 IU) or steroids (estradiol-17β, 1 mg plus progesterone, 2 mg) on the day after weaning. The plasma concentrations of LH and E for 10–12 days after weaning were compared with those of five untreated control sows. In the PMSG-treated group, concurrent peaks of LH (4.7 ± 0.5 ng/ml) and E (121 ± 41 pg/ml) were observed at estrus. The control group produced a lower LH peak at estrus (1.5 ± 0.4 ng/ml) which was not accompanied by a rise in plasma E. No consistent secretory pattern for plasma LH and E was observed in the steroid treatment group.

Effect of season on follicular dynamics and plasma concentrations of estradiol-17β, progesterone and luteinizing hormone in lactating Holstein cows

1994 ◽  
Vol 42 (8) ◽  
pp. 1263-1274 ◽  
Author(s):  
L. Badinga ◽  
W.W. Thatcher ◽  
C.J. Wilcox ◽  
G. Morris ◽  
K. Entwistle ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Plasma Concentrations ◽  
Holstein Cows ◽  
Estradiol 17Β ◽  
Follicular Dynamics

scholarly journals Risk of End-Stage Renal Disease in Psoriatic Patients: Real-World Data from a Nationwide Population-Based Cohort Study

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Eun Lee ◽  
Ju Hee Han ◽  
Chul Hwan Bang ◽  
Seung Ah Yoo ◽  
Kyung Do Han ◽  
...  
Keyword(s):  
Cohort Study ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Treated Group ◽  
Population Based ◽  
Control Group ◽  
Real World Data ◽  
History Of ◽  
Stage Renal Disease ◽  
End Stage

Abstract Psoriasis is a chronic inflammatory skin disorder mediated by the T-cell–related immune response. Psoriatic patients may have a variety of comorbidities, but their risk of end-stage renal disease (ESRD), particularly according to the subtype of psoriasis, is unclear. We investigated the risk of ESRD in patients with psoriasis according to the subtype of psoriasis and history of systemic therapy for psoriasis. A total of 2,121,228 adults (1,590,921 in the control group and 530,307 in the psoriasis group) were enrolled in this nationwide population-based cohort study until 2015. During follow-up, 1,434 of the subjects in the psoriasis group developed ESRD. After adjusting for confounding factors, psoriasis was associated with the risk of ESRD (hazard ratio (HR) 1.58, 95% confidence interval [95% CI] 1.47–1.68). The psoriatic arthritis group (HR 7.60, 95% CI 1.90–30.41) had a higher risk of ESRD than the control group. Interestingly, no such association was detected in the systemically treated group (HR 1.07, 95% CI 0.80–1.41). Moreover, the acitretin-treated group had a lower risk of ESRD (HR 0.658, 95% CI, 0.494–0.875) than the non-systemically treated group. In conclusion, the risk of developing ESRD in patients with psoriasis differed according to the type of treatment and the presence of arthritis.

scholarly journals Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients

2019 ◽  
Vol 2019 ◽  
pp. 1-9 ◽  
Author(s):  
Mining Liang ◽  
Beibei Zhang ◽  
Lu Deng ◽  
Rong Xu ◽  
Haishan Wu ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Lipid Metabolism ◽  
Bone Mineral ◽  
Treated Group ◽  
Control Group ◽  
Mineral Density ◽  
Insulin Levels ◽  
Glucose And Lipid Metabolism ◽  
History Of ◽  
Drug Naïve

Aim. To explore whether olanzapine alters bone mineral density (BMD), glucose, and lipid metabolism in schizophrenia patients. Methods. This study enrolled 150 patients diagnosed with schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), including 101 patients who had over 6-month history of olanzapine use (olanzapine-treated group) and 49 patients who had no history of antipsychotic use (first episode drug-naïve group). 71 subjects with age- and gender-matched healthy volunteers (healthy control group) were also enrolled. All study subjects were from the Chinese Han population recruited in the Second Xiangya Hospital from January 2015 to January 2016. Demographic and physical examination data were collected from all subjects. BMD measurements of the radius+ulna, lumbar spine (L1-4), and left hip were performed via a dual-energy X-ray absorptiometry test. Serum lipid, glucose, and insulin levels were analyzed. Psychopathology profiles in all enrolled schizophrenia patients were assessed by the positive and negative syndrome scale (PANSS). Results. There was no significant difference in age, gender, activity intensity, smoking, or drinking among the three groups. In the majority of evaluated bone areas, the BMD values in olanzapine-treated or drug-naïve patients were lower than those in the control group. However, BMD values in the drug-naïve group showed no difference or even decreased as compared with those in the olanzapine-treated group. Among the olanzapine-treated group, although not observed in every tested region, a positive correlation was found of BMI or HOMA-IR with BMD. Stepwise multiple linear regression analysis revealed independent predictive factors associated with BMD in groups/subgroups of schizophrenia patients or healthy controls, including gender, TG, BMI, body weight, HOMA-IR, and FBG. Conclusions. Schizophrenia, but not the long-term use of olanzapine, correlates with BMD loss in schizophrenia patients. Elevated BMI, TG, FBG, and insulin levels might protect these patients against bone degradation. Our work provides new information to improve the understanding, prevention, and treatment of osteoporosis in schizophrenia patients.

ESTRUS AND PREGNANCY IN PRIMIPAROUS SOWS TREATED WITH PREGNANT MARE’S SERUM GONADOTROPIN OR ESTRADIOL-17β AND PROGESTERONE

1976 ◽  
Vol 56 (4) ◽  
pp. 693-698 ◽  
Author(s):  
G. W. DYCK
Keyword(s):  
Pregnancy Rates ◽  
History Of ◽  
Serum Gonadotropin ◽  
The Mean ◽  
And Control ◽  
Mean Time ◽  
Estradiol 17Β ◽  
Stimulation Of

Over a 3-yr period, the effectiveness of pregnant mare’s serum gonadotropin (PMSG-1,500 IU) or estradiol-17β (1 mg) plus progesterone (2 mg) for the stimulation of post-weaning estrus and conception in primiparous sows from a herd with a history of post-weaning anestrus was evaluated. On the day after weaning, an intramuscular (i.m.) injection of PMSG or steroids was given to 49 and 51 sows, respectively. Fifty untreated sows served as controls. Treated sows in estrus by day 8 and control sows in estrus by day 40 were bred on the 2nd day of estrus. Serviced sows were killed at day 25 of pregnancy or on the day after return to estrus. The remaining sows were killed when in estrus or between days 41 and 45 after weaning. By day 8, more (P < 0.01) PMSG-treated (98.0%) sows were in estrus than either the steroid-treated (64.7%) or control (66.0%) sows. By day 14, fewer (P < 0.05) steroid-treated than control sows were in estrus (64.7 vs. 82.0%). The mean interval between weaning and estrus for sows in estrus by day 8 was less for the PMSG (P < 0.01) - and steroid (P < 0.05) - treated sows than for the control sows (3.83 ± 0.11 and 4.36 ± 0.28 vs. 5.12 ± 0.23 days). For the steroid-treated and control sows in estrus after day 8, the mean time to estrus was 34.6 ± 3.5 and 21.2 ± 2.8 days, respectively (P < 0.01). Pregnancy rates were similar for the PMSG and steroid treatments (57.1 and 47.0%), and lower than for the control sows (84.0%). The PMSG-treated animals had larger litters (16.4 ± 1.0 embryos) than either the steroid-treated (12.8 ± 1.1 embryos) or control (11.3 ± 0.8 embryos) animals.

Allergy

PEDIATRICS ◽  
1990 ◽  
Vol 85 (5) ◽  
pp. 911-916
Keyword(s):  
Breast Feeding ◽  
Gastrointestinal Disease ◽  
Study Groups ◽  
Treated Group ◽  
Skin Tests ◽  
Control Group ◽  
Solid Foods ◽  
Pregnancy And Lactation ◽  
History Of ◽  
Intensive Education

Study Population Study infants were born between November 12, 1981 and July 25, 1984. They were selected from a group who had parents with a history of atopy. Methods Participants were divided into two groups. I. Prophylaxis Group (N = 103). During the third trimester and while they were breast-feeding, women were instructed to avoid totally all milk, egg, and peanut products, to avoid concentrated soy (tofu), to limit wheat to no more than two servings daily, and to use other grains to fulfill their cereal and starch needs. They were also given prenatal vitamins and calcium supplements of 1500 mg daily. When breast-feeding was stopped, Nutramigen was to be fed to the baby until 12 months of age. They were to avoid solid foods until 6 months of age, starting with nonlegume vegetables followed by rice at 7 months, meat at 8 months, noncitrus juices at 9 months, cow's milk at 12 months, and wheat, soy, corn, and citrus thereafter at monthly intervals. II. Control Group (N = 185). Women in the control group were encouraged to follow standard diets for pregnancy and lactation, and they were given Enfamil when discontinuing breast-feeding. They were instructed to introduce solid foods as per the American Academy of Pediatrics recommendation. III. Common to both study groups were the encouragement of breast-feeding for at least 4 to 6 months and the use of Tri-Vi-Flor. Parents were given intensive education on reducing environmental allergens and tobacco smoke in the house. Findings The cumulative prevalence of atopy was lower at 12 months in the prophylactic-treated group (16.2%) compared to the control group (27.1%), resulting from reduced food-associated atopic dermatitis, urticaria and/or gastrointestinal disease by 12 months (5.1% vs 16.4%), caused primarily by fewer positive mild skin tests (1% vs 12.4%).

scholarly journals Changes in Plasma Concentrations of Luteinizing Hormone, Progesterone, and Estradiol-17β in Peripubertal Turkey Hens under Constant or Diurnal Lighting1

2002 ◽  
Vol 67 (2) ◽  
pp. 591-598 ◽  
Author(s):  
Wayne L. Bacon ◽  
Jorge A. Vizcarra ◽  
James L.M. Morgan ◽  
Jingying Yang ◽  
Han-Ken Liu ◽  
...  
Keyword(s):  
Luteinizing Hormone ◽  
Plasma Concentrations ◽  
Estradiol 17Β

scholarly journals Efavirenz Is Not Associated with an Increased Risk of Depressive Disorders in Patients Living with HIV: An 11-Year Population-Based Study in Taiwan

Healthcare ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1625
Author(s):  
Chia-Wen Li ◽  
Yen-Chin Chen ◽  
Nan-Yao Lee ◽  
Po-Lin Chen ◽  
Ming-Chi Li ◽  
...  
Keyword(s):  
Depressive Disorders ◽  
Past History ◽  
Treated Group ◽  
Population Based ◽  
Insurance Premium ◽  
Control Group ◽  
Hazard Ratios ◽  
Increased Risk ◽  
History Of ◽  
Southern Taiwan

(1) Background: This study aimed to determine the association between the use of efavirenz and depressive disorders among human immunodeficiency virus (HIV)-infected patients. (2) Methods: A retrospective cohort study was conducted using Taiwan’s National Health Insurance Database. We identified patients receiving anti-retroviral therapy (ART) between 2000 and 2009; these patients were followed until 2010 for diagnoses of depressive disorders using the Cox proportional hazard model to estimate hazard ratios. (3) Results: After up to 11 years of follow-up, the incidence of depressive disorders for the efavirenz-treated group was estimated at 12.2/1000 person-years (PYs), and the control group was at 12.5/1000 PY (p = 0.822). The independent risk factors for depressive disorders included an insurance premium of less than NTD 17,820 (New Taiwan Dollars—NTD) (adjusted hazard ratio (aHR) 2.59, 95% confidence interval (CI), 1.79–3.76, p < 0.001), and between NTD 17,821 and NTD 26,400 (aHR 1.55, 95% CI, 1.04–2.31, p = 0.030), living in Southern Taiwan (aHR 1.49, 95% CI, 1.21–1.84, p = 0.002), and with a psychiatric history (excluding depressive disorders) (aHR 4.59, 95% CI, 3.51–6.01, p = 0.030). (4) Conclusions: This study concluded that ART-treated patients with a past history of psychiatric disorders, lower insurance premium, and living in Southern Taiwan have an increased risk of depressive disorders, which are not associated with the use of efavirenz.

Sign in / Sign up

Export Citation Format

Share Document